March 29, 2022

While the Association for Clinical Oncology (ASCO) strongly believes in the stated mission of ARPA-H and its potential to innovate and expedite research, we are concerned that the Administration’s FY 2023 budget request invests in ARPA-H at the expense of the National Institutes of Health (NIH) and the National Cancer Institute (NCI)

March 14, 2022

Patients with advanced non-small cell lung cancer without EGFR/ALK mutations who were treated with toripalimab plus first-line chemotherapy had better progression-free survival and overall survival compared to patients who received chemotherapy alone, according to research from the CHOICE-01 trial. 

March 14, 2022

In patients with previously untreated metastatic or unresectable melanoma, the combination of nivolumab and relatlimab continued to demonstrate a progression-free survival benefit compared to nivolumab alone. The combination also demonstrated for the first time a higher overall response rate according to follow-up data from the RELATIVITY-047 trial. These data will be presented during an ASCO Plenary Series session taking place March 15, 2022, at 5:00 p.m. ET.

February 22, 2022

ALEXANDRIA, Va. – Jeffrey Peppercorn, MD, MPH, has been appointed as the next Editor-in-Chief of JCO Oncology Practice (JCO OP), an American Society of Clinical Oncology (ASCO) journal. JCO OP publishes impactful information and insights to keep oncology practice current on changes and challenges inherent in delivering equitable, high-quality oncology care with an evolving value-based lens.

 

February 15, 2022

The Association for Clinical Oncology (ASCO) congratulates Robert M. Califf, MD, on his confirmation by the United States Senate to serve as the next Commissioner of the U.S. Food and Drug Administration (FDA). 

February 14, 2022

Taking aspirin daily did not improve invasive disease-free survival (iDFS) in breast cancer patients, according to research being presented in the February 15, 2022 ASCO Plenary Series session. 

February 14, 2022

Pancreatic cancer is a leading cause of cancer-related deaths; however, despite decades of research, limited progress has been made to improve survival. There are currently no FDA-approved treatment options for patients with pancreatic cancer that has progressed on first- and second-line chemotherapy. Sotorasib is active and well tolerated in patients with metastatic pancreatic cancer with a KRASG12C mutation, according to research being presented in the February 15, 2022, ASCO Plenary Series session.

February 14, 2022

A scoring algorithm that incorporated 290 genetic variants for prostate cancer (PHS290) accurately identified people with high or low lifetime risks of developing metastatic prostate cancer or dying from the disease. Based on the risk scores, people with an African ancestry had the highest risk of developing metastatic prostate cancer and dying of the disease. The study will be presented at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, taking place February 17-19, 2022, in San Francisco, California.

February 3, 2022

“This year’s World Cancer Day theme, ‘Close the Care Gap,’ speaks to the heart of what it means to achieve progress against cancer today." 

February 3, 2022

Findings on a scoring algorithm for predicting the risk of developing metastatic or fatal prostate cancer will be highlighted in the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium’s official Press Program. Studies featured in the Press Program are among the nearly 600 abstracts that will be presented at the Symposium. 

February 2, 2022

The Association for Clinical Oncology (ASCO) applauds President Biden for his decision to relaunch the Cancer Moonshot with ambitious and worthy goals of reducing the death rate from cancer and improving the experience of patients and families living with cancer.

February 1, 2022

On February 1, 2022, the American Society of Clinical Oncology (ASCO) and the American Cancer Society (ACS) initiated a collaboration to ensure that people can easily find the trusted, expert-approved cancer content they need when turning to either organization for information. As an initial step, the organizations are cross-sharing select cancer prevention, screening, and survivorship resources on their patient and consumer education websites, Cancer.Net and Cancer.org.

January 24, 2022

In patients with advanced gastrointestinal stromal tumors (GIST) that progressed on or were intolerant to imatinib, the efficacy of ripretinib was comparable to sunitinib. These findings from the INTRIGUE trial were presented during the January session of the American Society of Clinical Oncology (ASCO) Plenary Series. 

January 18, 2022

Results from the randomized international phase III TOPAZ-1 trial showed that the checkpoint immunotherapy durvalumab (Imfinzi) plus chemotherapy drugs gemcitabine and cisplatin significantly improved overall survival in patients with advanced biliary tract cancer compared to patients who received a placebo plus the chemotherapy drugs. Biliary tract cancer is classified as a rare disease comprised primarily of bile duct and gallbladder cancers.

January 18, 2022

Results from the randomized international phase III HIMALAYA trial showed that a combination of durvalumab (Imfinzi) plus the experimental drug tremelimumab, both immunotherapies, significantly improved overall survival in patients with advanced, unresectable hepatocellular carcinoma, the most common type of liver cancer, compared to patients who received only sorafenib (Nexavar). 

Pages